Previous 10 | Next 10 |
2023-12-15 13:25:40 ET Gainers: Getaround ( GETR ) +116% . Battalion Oil Corp ( BATL ) +82% . La Rosa Holdings Corp. ( LRHC ) +45% . Verrica Pharmaceuticals ( VRCA ) +37% . Bruush Oral Care ( BRSH ) +36% . NCS Multistage Hold...
2023-12-15 10:00:27 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom For further details see: Myomo, Aileron...
2023-12-15 08:38:22 ET Losers: Aadi Bioscience AADI -54% on study data for anti-tumor drug . Inno Holdings ( INHD ) -45% . Eos Energy Enterprises EOSE -23% announces launch of proposed $40M public offering . Chavant Capital Acquisition Corp ( CLAY...
2023-11-06 12:51:18 ET Gainers: MSP Recovery ( LIFW ) +458% . Bluegreen Vacations Holding Corporation ( BVH ) +106% . Tenon Medical ( TNON ) +72% . Cano Health ( CANO ) +43% . Cheetah Net Supply Chain Service ( CTNT ) +36% . ...
2023-11-01 14:50:52 ET More on Aileron Financial information for Aileron Therapeutics For further details see: Aileron gains after all-stock deal to acquire Lung Therapeutics
Aileron Therapeutics Announces Acquisition of Lung Therapeutics PR Newswire Acquisition includes multiple clinical stage, orphan pulmonary disease candidates, including LTI-03, a Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibros...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q3 2023
Aileron Therapeutics ( NASDAQ: ALRN ) shed ~38% on Tuesday after the company disclosed plans to explore strategic alternatives, including a sale, and said that its Phase 1b study for chemoprotective agent ALRN-6924 failed in patients with p53-mutated breast cancer. The open-label ...
BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN) today announced that a review of initial data from its Phase 1b chemoprotection trial of ALRN-6924 in patients with p53-mutated breast cancer showed that patients in the trial experienced severe neutropenia (Grade 4) an...
BOSTON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that it received written notice on November 28, 2022 from The N...
News, Short Squeeze, Breakout and More Instantly...
Aileron Therapeutics Inc. Company Name:
ALRN Stock Symbol:
NASDAQ Market:
Aileron Therapeutics Inc. Website:
Announced positive data from Cohort 1 of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) patients with positive trends observed in seven of the eight biomarkers evaluated Topline results from Cohort 2 evaluating high-dose LTI-03 (5 mg BID) expected in ...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...
AUSTIN, Texas, May 06, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ:ALRN), a biopharmaceutical company advancing a no...